rs141921797
Positions:
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 0P and 3B. BP4_ModerateBP6
The NM_000051.4(ATM):āc.4082A>Gā(p.Gln1361Arg) variant causes a missense change. The variant allele was found at a frequency of 0.0000552 in 1,613,460 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: š 0.00027 ( 0 hom., cov: 32)
Exomes š: 0.000033 ( 0 hom. )
Consequence
ATM
NM_000051.4 missense
NM_000051.4 missense
Scores
1
3
15
Clinical Significance
Conservation
PhyloP100: 5.58
Genes affected
ATM (HGNC:795): (ATM serine/threonine kinase) The protein encoded by this gene belongs to the PI3/PI4-kinase family. This protein is an important cell cycle checkpoint kinase that phosphorylates; thus, it functions as a regulator of a wide variety of downstream proteins, including tumor suppressor proteins p53 and BRCA1, checkpoint kinase CHK2, checkpoint proteins RAD17 and RAD9, and DNA repair protein NBS1. This protein and the closely related kinase ATR are thought to be master controllers of cell cycle checkpoint signaling pathways that are required for cell response to DNA damage and for genome stability. Mutations in this gene are associated with ataxia telangiectasia, an autosomal recessive disorder. [provided by RefSeq, Aug 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -3 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.07235512).
BP6
Variant 11-108287688-A-G is Benign according to our data. Variant chr11-108287688-A-G is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 185234.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=3, Uncertain_significance=9}.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATM | NM_000051.4 | c.4082A>G | p.Gln1361Arg | missense_variant | 27/63 | ENST00000675843.1 | NP_000042.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ATM | ENST00000675843.1 | c.4082A>G | p.Gln1361Arg | missense_variant | 27/63 | NM_000051.4 | ENSP00000501606.1 |
Frequencies
GnomAD3 genomes AF: 0.000263 AC: 40AN: 152234Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
40
AN:
152234
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000483 AC: 12AN: 248700Hom.: 0 AF XY: 0.0000446 AC XY: 6AN XY: 134634
GnomAD3 exomes
AF:
AC:
12
AN:
248700
Hom.:
AF XY:
AC XY:
6
AN XY:
134634
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000329 AC: 48AN: 1461108Hom.: 0 Cov.: 30 AF XY: 0.0000344 AC XY: 25AN XY: 726880
GnomAD4 exome
AF:
AC:
48
AN:
1461108
Hom.:
Cov.:
30
AF XY:
AC XY:
25
AN XY:
726880
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000269 AC: 41AN: 152352Hom.: 0 Cov.: 32 AF XY: 0.000242 AC XY: 18AN XY: 74504
GnomAD4 genome
AF:
AC:
41
AN:
152352
Hom.:
Cov.:
32
AF XY:
AC XY:
18
AN XY:
74504
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
1
ESP6500EA
AF:
AC:
0
ExAC
AF:
AC:
8
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:11Benign:3
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Ataxia-telangiectasia syndrome Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 25, 2022 | This sequence change replaces glutamine, which is neutral and polar, with arginine, which is basic and polar, at codon 1361 of the ATM protein (p.Gln1361Arg). This variant is present in population databases (rs141921797, gnomAD 0.06%). This missense change has been observed in individual(s) with colon cancer or melanoma (PMID: 29684080, 34262154). ClinVar contains an entry for this variant (Variation ID: 185234). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mendelics | Jul 02, 2018 | - - |
not provided Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Athena Diagnostics | Dec 30, 2019 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Nov 21, 2024 | Observed in individuals with melanoma, prostate, colorectal, breast, and renal cancer (PMID: 29684080, 34262154, 35264596, 36898365, 31206626); In silico analysis indicates that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 23555315, 29684080, 31871109, 34262154, 35264596, 36898365, 39324485, 31206626) - |
Likely benign, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Jun 21, 2023 | - - |
Familial cancer of breast Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | KCCC/NGS Laboratory, Kuwait Cancer Control Center | Jun 06, 2023 | A variant of uncertain significance was detected in the ATM gene. This sequence change replaces glutamine with arginine at codon 1361 of the ATM protein (p.Gln1361Arg). This variant is present in population databases (rs141921797, ExAC 0.07%). This variant has been observed in individual(s) with breast cancer (PMID: 23555315). ClinVar contains an entry for this variant (Variation ID: 185234). In-silico predictions show benign computational verdict based on 9 benign predictions from PolyPhen, BayesDel_addAF, DEOGEN2, EIGEN, LIST-S2, MVP, MutationTaster, PrimateAI and SIFT vs 4 pathogenic predictions from DANN, FATHMM-MKL, M-CAP and MutationAssessor and the position is not highly conserved. Therefore, it has been classified as a Variant of Uncertain Significance. Heterozygous pathogenic/likely pathogenic mutations in ATM gene cause breast cancer susceptibility (OMIM#114480). - |
Uncertain significance, criteria provided, single submitter | clinical testing | St. Jude Molecular Pathology, St. Jude Children's Research Hospital | Oct 13, 2022 | The ATM c.4082A>G (p.Gln1361Arg) missense change has a maximum subpopulation frequency of 0.060% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL predicts a benign effect on protein function, but to our knowledge this prediction has not been confirmed by functional studies. This variant was reported in five individuals in a study of breast cancer, however it was not specified if the variant was found in cases or controls (PMID: 31871109). This variant is present in nine individuals in a database of women older than 70 years of age who have never had cancer (FLOSSIES database, https://whi.color.com/). To our knowledge, this variant has not been reported in individuals with ataxia telangiectasia. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. - |
Likely benign, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | May 16, 2024 | This variant is considered likely benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 25085752]. - |
not specified Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 18, 2024 | Variant summary: ATM c.4082A>G (p.Gln1361Arg) results in a conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 4.8e-05 in 248700 control chromosomes, predominantly at a frequency of 0.00062 within the African or African-American subpopulation in the gnomAD database. This frequency is not significantly higher than estimated for a pathogenic variant in ATM causing Breast Cancer (4.8e-05 vs 0.001), allowing no conclusion about variant significance In addition, this variant has also been reported in 4/7325 European American and 5/2559 African American (i.e. with an allele frequency of 0.000977) women who were older than age 70 and cancer free (in the FLOSSIES database). The variant, c.4082A>G, has also been reported in the literature in cohorts of individuals affected with various tumor phenotypes, but without providing information on the associated phenotypes (examples: Haiman_2013, Yehia_2018, Adedokun_2020 and Dalmasso_2021). These report(s) do not provide unequivocal conclusions about association of the variant with Breast Cancer. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 23555315, 29684080, 31871109, 34262154). ClinVar contains an entry for this variant (Variation ID: 185234). Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Oct 28, 2019 | - - |
Hereditary cancer-predisposing syndrome Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 22, 2022 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Jul 26, 2022 | This missense variant replaces glutamine with arginine at codon 1361 of the ATM protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with melanoma (PMID: 34262154) and five carriers in a breast cancer case-control study, however the cancer status of the carriers were not specified (PMID: 31871109). This variant also has been reported in 9 individuals age 70 years or older without cancer (FLOSSIES; https://whi.color.com/variant/11-108158415-A-G). This variant has been identified in 17/280106 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
ATM-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 08, 2024 | The ATM c.4082A>G variant is predicted to result in the amino acid substitution p.Gln1361Arg. This variant was reported in several individuals with breast cancer (Table 5, Adedokun et al. 2020. PubMed ID: 31871109; Supp. Table 3, Guindalini et al. 2022. PubMed ID: 35264596; Table 3, Weitzel et al. 2019. PubMed ID: 31206626), in an individual with sporadic melanoma (Table S2, Dalmasso et al. 2021. PubMed ID: 34262154), and in an individual with Cowden syndrome (Table S9, Yehia et al. 2018. PubMed ID: 29684080). This variant is reported in 0.060% of alleles in individuals of African descent in gnomAD and is interpreted as a variant of uncertain significance by the vast majority of submitters in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/185234/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
.;T;T;T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Pathogenic
D
LIST_S2
Benign
T;T;.;T
M_CAP
Benign
D
MetaRNN
Benign
T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Uncertain
.;M;M;.
PrimateAI
Benign
T
PROVEAN
Benign
N;N;N;.
REVEL
Benign
Sift
Benign
T;T;T;.
Sift4G
Uncertain
D;T;T;T
Polyphen
0.012
.;B;B;.
Vest4
0.38, 0.40
MVP
MPC
0.14
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at